362505-84-8

Basic information

• Product Name: Relacatib
• Synonyms: Relacatib;SB-462795;N2-(1-Benzofuran-2-ylcarbonyl)-N1-[(7R)-methyl-3-oxo-1-(2-pyridinylsulfonyl)perhydroazepin-4(S)-yl]-L-leucinamide;N-[(1S)-1-[[[(4S,7R)-Hexahydro-7-methyl-3-oxo-1-(2-pyridinylsulfonyl)-1H-azepin-4-yl]amino]carbonyl]-3-methylbutyl]-2-benzofurancarboxamide;N-[(2S)-4-methyl-1-[[(4S,7R)-7-methyl-3-oxo-1-pyridin-2-ylsulfonylazepan-4-yl]amino]-1-oxopentan-2-yl]-1-benzofuran-2-carboxamide
• CAS NO: 362505-84-8
• Molecular Formula: C27H32N4O6S
• Molecular Weight: 540.63118
• Mol File: 362505-84-8.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.34 g/cm³
• CAS DataBase Reference: Relacatib(CAS DataBase Reference)
• NIST Chemistry Reference: Relacatib(362505-84-8)
• EPA Substance Registry System: Relacatib(362505-84-8)

Safety Data

• Hazardous Substances Data: 362505-84-8(Hazardous Substances Data)

Usage

Uses

Treatment of osteoporosis.

Upstream product

• 87413-09-0 Dess-Martin periodane 
• 362507-77-5 N-[(1S)-1-({[(3S,4S,7R)-3-hydroxy-7-methyl-1-(2-pyridinylsulfonyl)hexahydro-1H-azepin-4-yl]-amino}carbonyl)-3-methylbutyl]-1-benzofuran-2-carboxamide 
• 362509-50-0 allyl-(1-methylpent-4-enyl)amine 
• 35021-88-6 allyl(1-methylpent-4-enylidene)amine 
• 403700-44-7 5-((S)-2-tert-butoxycarbonylamino-4-methylpentanoylamino)-6-hydroxy-2-methylazepane-1-carboxylic acid benzyl ester 
• 883231-93-4 {1-[3-hydroxy-7-methyl-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl}-carbamic acid tert-butyl ester 
• 403700-47-0 (S)-2-Amino-4-methyl-pentanoic acid [3-hydroxy-7-methyl-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide 
• 403700-45-8 [(S)-1-(3-hydroxy-7-methylazepan-4-ylcarbamoyl)-3-methylbutyl]carbamic acid tert-butyl ester 
• 362509-54-4 allyl(1-methylpent-4-enyl)carbamic acid benzyl ester 
• 362509-57-7 2-methyl-2,3,4,7-tetrahydro-azepine-1-carboxylic acid benzyl ester 
• 403700-48-1 benzofuran-2-carboxylic acid {(S)-1-[3-hydroxy-7-methyl-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-3-methylbutyl}amide 
• 13139-15-6 N-tert-butoxycarbonyl-L-leucine 
• 109-49-9 5-Hexen-2-one 

Relevant articles and documents

A scalable oxidation for the final stage of synthesis of cathepsin K inhibitor SB-462795

In developing the manufacturing route for the cathepsin K inhibitor SB-462795, the oxidation of a secondary alcohol for the final chemical stage is described. Prospective conditions were limited by several factors, particularly general safety concerns of oxidation reactions, the requirement to control impurities and transition metals isolated in the final product, and the desire to reduce the environmental impact. Two N-oxy free radical approaches (TEMPO and PIPO) and Moffatt conditions were evaluated in depth for their potential to achieve the targets. For reasons of robustness, scalability, and cost-effectiveness, the Moffatt conditions were the best manufacturing option.

Method of Preparation of Benzofuran-2-Carboxylic Acid -Amide

This invention relates to a method of preparation of benzofuran-2-carboxylic acid {(S)-3-methyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide.

Protease inhibitors

The present invention provides C1-6alkyl-4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease; and parasitic diseases, including malaria, by administering to a patient in need thereof one or more compounds of the present invention.